Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
← catalyst calendarNCT04743141 · readout in 1,442 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
600estimated
Sites
124
Countries
Poland, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-04-28 | actual | When the study began enrolling |
| Primary completion | 2030-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acute Treatment of Migraine
Intervention
- Drug: Rimegepant (PF-07899801)
Primary outcome
what the primary-completion date above is the date OFThe frequency and severity of on-treatment and treatment-emergent adverse events, serious adverse events, adverse events leading to discontinuation, clinically significant lab abnormalities
measured 58 weeks
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed